Asserter profile

HALOZYME, INC.

operating company13 patents now16 ever5 cases filed during tenure4 connections

Also seen as: Halozyme, Inc.

PTAB exposure

13of this entity’s patents have been challenged at PTAB (13 total proceedings). 10 had claims invalidated. 2 currently have active proceedings.

Final written decisions are public record. The invalidation grounds usually carry over as § 102 / § 103 ammunition in district court — see IPR estoppel.

Two-hop network

Edges marked ⚖️ overlap with at least one infringement suit filed during the receiving entity’s tenure with the patent. Bold-bordered = this entity. Red = NPE; orange = shell LLC; green = defensive aggregator; blue = operating company.

flowchart LR
    Nhalozyme["HALOZYME, INC."]
    Nhalozyme_therapeutics["HALOZYME THERAPEUTICS, INC."]
    Nshepard_h_michael["SHEPARD, H. MICHAEL"]
    Nh_michael_shepard["H. Michael Shepard"]
    Nshepard_michael_h["SHEPARD, MICHAEL H."]
    Nconnor_robert_james_wei_ge_zhao_qiping_shepard_h_michael["CONNOR, ROBERT JAMES; WEI, GE; ZHAO, QI…"]
    Nconnor_robert_james_wei_ge_zhao_qiping["CONNOR, ROBERT JAMES; WEI, GE; ZHAO, Qi…"]
    Nconnor_robert_james["CONNOR, ROBERT JAMES"]
    Nwei_ge["WEI, GE"]
    Nzhao_qiping["ZHAO, QIPING"]
    Nrobert_james_connor_ge_wei_qiping_zhao["Robert James Connor, Ge Wei, Qiping Zhao"]
    Nhalozyme_therapeutics -->|"2024 · Assignment · 12264345"| Nhalozyme
    Nhalozyme_therapeutics -->|"2023 · Assignment · 12371685"| Nhalozyme
    Nshepard_h_michael -->|"2023 · Assignment · 12371685"| Nhalozyme
    Nhalozyme_therapeutics -->|"2020 · ASSIGNMENT OF ASSIGNORS INTEREST · 11041149"| Nhalozyme
    Nshepard_h_michael ==>|"⚖️ 2020 · ASSIGNMENT OF ASSIGNORS INTEREST · 11041149"| Nhalozyme
    Nhalozyme_therapeutics -->|"2016 · Assignment of Assignors Interest · 10865400"| Nhalozyme
    Nshepard_h_michael ==>|"⚖️ 2016 · Assignment of Assignors Interest · 10865400"| Nhalozyme
    Nshepard_h_michael -->|"2023 · Assignment · 12152262"| Nhalozyme
    Nhalozyme_therapeutics -->|"2023 · Assignment · 12152262"| Nhalozyme
    Nhalozyme_therapeutics -->|"2023 · Assignment · 12018298"| Nhalozyme
    Nshepard_h_michael -->|"2023 · Assignment · 11952600"| Nhalozyme
    Nhalozyme_therapeutics -->|"2022 · ASSIGNMENT OF ASSIGNORS INTEREST · 12123035"| Nhalozyme
    Nshepard_h_michael -->|"2022 · ASSIGNMENT OF ASSIGNORS INTEREST · 12123035"| Nhalozyme
    Nhalozyme_therapeutics -->|"2022 · Assignment · 12110520"| Nhalozyme
    Nh_michael_shepard ==>|"⚖️ 2022 · Assignment · 12110520"| Nhalozyme
    Nshepard_michael_h -->|"2024 · Assignment · 12104185"| Nhalozyme
    Nhalozyme_therapeutics -->|"2024 · Assignment · 12104185"| Nhalozyme
    Nhalozyme_therapeutics -->|"2022 · Assignment · 12049652"| Nhalozyme
    Nshepard_h_michael ==>|"⚖️ 2022 · Assignment · 12049652"| Nhalozyme
    Nh_michael_shepard -->|"2021 · Assignment · 12091692"| Nhalozyme
    Nhalozyme_therapeutics ==>|"⚖️ 2021 · Assignment · 12091692"| Nhalozyme
    Nshepard_h_michael -->|"2023 · Assignment · 12077791"| Nhalozyme
    Nhalozyme_therapeutics -->|"2023 · Assignment · 12077791"| Nhalozyme
    Nhalozyme_therapeutics -->|"2022 · Assignment · 12054758"| Nhalozyme
    Nshepard_h_michael -->|"2022 · Assignment · 12054758"| Nhalozyme
    Nshepard_h_michael -->|"2021 · Assignment · 12037618"| Nhalozyme
    Nhalozyme_therapeutics -->|"2021 · Assignment · 12037618"| Nhalozyme
    Nhalozyme_therapeutics -->|"2013 · Assignment · 9447401"| Nhalozyme
    Nshepard_h_michael -->|"2013 · Assignment · 9447401"| Nhalozyme
    Nconnor_robert_james_wei_ge_zhao_qiping_shepard_h_michael -->|"2024 · Assignment · 12264345"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2023 · Assignment · 12371685"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2020 · ASSIGNMENT OF ASSIGNORS INTEREST · 11041149"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2016 · Assignment of Assignors Interest · 10865400"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2020 · Assignment · 11066656"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2023 · Assignment · 12152262"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2023 · Assignment · 11952600"| Nhalozyme_therapeutics
    Nconnor_robert_james -->|"2022 · ASSIGNMENT OF ASSIGNORS INTEREST · 12123035"| Nhalozyme_therapeutics
    Nwei_ge -->|"2022 · ASSIGNMENT OF ASSIGNORS INTEREST · 12123035"| Nhalozyme_therapeutics
    Nzhao_qiping -->|"2022 · ASSIGNMENT OF ASSIGNORS INTEREST · 12123035"| Nhalozyme_therapeutics
    Nrobert_james_connor_ge_wei_qiping_zhao -->|"2022 · Assignment · 12110520"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2024 · Assignment · 12104185"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2022 · Assignment · 12049652"| Nhalozyme_therapeutics
    Nrobert_james_connor_ge_wei_qiping_zhao -->|"2021 · Assignment · 12091692"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2023 · Assignment · 12077791"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2022 · Assignment · 12054758"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2021 · Assignment · 12037618"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2021 · Correction · 12037618"| Nhalozyme_therapeutics
    Nconnor_robert_james_wei_ge_zhao_qiping -->|"2013 · Assignment · 9447401"| Nhalozyme_therapeutics
    classDef focal fill:#fef3c7,stroke:#92400e,stroke-width:3px,color:#1c1917
    classDef npe fill:#fee2e2,stroke:#be123c,stroke-width:2px,color:#1c1917
    classDef shell fill:#fed7aa,stroke:#9a3412,stroke-width:2px,color:#1c1917
    classDef defensive fill:#dcfce7,stroke:#15803d,stroke-width:2px,color:#1c1917
    classDef operating fill:#e0f2fe,stroke:#075985,stroke-width:1px,color:#1c1917
    class Nhalozyme focal
    class Nhalozyme_therapeutics operating

Patents currently held (13)

Patents previously held (3)

Connected entities (4)

Correspondent attorneys (9)

Attorneys / firms recorded with USPTO when this entity received a patent. Recurrence is the signal — many firms do both NPE and operating-company patent work, so a single appearance doesn’t mean much.